exRNAdisease

General Information

Database ID:

exR0087926

RNA Name:

hsa-miR-214-3p

RNA Type:

miRNA

Chromosome:

chr1

Starnd:

Coordinate:

Start Site(bp):

172138816

End Site(bp):

172138837

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
MTMR12	chr5	32226994	32312987	-
AP3M1	chr10	74120255	74151063	-
AMER1	chrX	64185117	64205708	-
GDI1	chrX	154436913	154443467	+
RPUSD1	chr16	784974	788397	-
SMG5	chr1	156249224	156282825	-
DHX36	chr3	154272546	154324487	-
PIP5K1C	chr19	3630183	3700479	-
C19orf47	chr19	40319536	40348527	-
MTMR3	chr22	29883155	30030866	+
ABHD2	chr15	89087459	89202355	+
MAPKAPK2	chr1	206684944	206734283	+
RHPN1	chr8	143368876	143384221	+
HDLBP	chr2	241227264	241317061	-
ARHGAP35	chr19	46860997	47005077	+
YWHAB	chr20	44885702	44908532	+
WDR5	chr9	134135365	134159968	+
RPS6KA1	chr1	26529761	26575030	+
JPT1	chr17	75135248	75168281	-
SEC61A1	chr3	128051641	128071683	+
TMEM161B	chr5	88189633	88269476	-
NECTIN1	chr11	119623408	119729200	-
SOX11	chr2	5692384	5701385	+
MYH9	chr22	36281277	36388067	-
RAB15	chr14	64945814	64973226	-
PLAGL2	chr20	32192504	32207743	-
TGIF2	chr20	36573488	36593950	+
NRIP1	chr21	14961235	15065936	-
LYSMD2	chr15	51723011	51751585	-
KMT2D	chr12	49018975	49059774	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000540	chr14	55799534	55821940	+
hsa_circ_0001168	chr20	47691321	47707559	+
hsa_circ_0001146	chr20	34241449	34246936	-
hsa_circ_0000799	chr17	65941524	65972074	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC008040.1	chr3	169939353	169966734	-
AC010442.1	chr5	466124	473098	-
AC016876.2	chr17	7581964	7584086	-
AC068790.9	chr12	124085761	124088598	+
AC109460.3	chr16	28974804	28990775	+
ADAMTSL4-AS1	chr1	150560202	150574552	-
AL031282.2	chr1	1702736	1737688	-
AL160006.1	chr1	110058340	110062555	+
EPB41L4A-AS1	chr5	112160526	112164818	+
FGD5-AS1	chr3	14920347	14948424	-
LINC00665	chr19	36313067	36331770	-
LINC01535	chr19	37251885	37265535	+
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
POLR2J4	chr7	43940895	44019175	-
SNHG16	chr17	76557764	76565348	+
STAG3L5P-PVRIG2P-PILRB	chr7	100336104	100367831	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.